Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.
Also called NCT05196347
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 180 participants
- Sponsor
- Kaohsiung Medical University
- Registry
-
NCT05196347
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT05196347. Randomized; no masking; primary purpose treatment. Start 2022-05-27 (actual); primary completion 2024-08-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease
- Acronym
- DAPA-advKD
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- Kaohsiung Medical University
Record details
- Record id
cardio:ct-nct05196347- Content hash
d2498248c8735ba15cc92ec1ed32a3d0c73e6813758a05fb1f29b9802be16469